US 12,215,145 B2
Treatment of headache using anti-CGRP antibodies
Roger K. Cady, Bothell, WA (US); Jeffrey T. L. Smith, Dublin (IE); Joseph Hirman, Bothell, WA (US); Barbara Schaeffler, Bothell, WA (US); and Lahar Mehta, Valby (DK)
Assigned to H. LUNDBECK A/S, Valby (DK)
Filed by H. LUNDBECK A/S, Valby (DK)
Filed on Mar. 19, 2024, as Appl. No. 18/609,247.
Application 18/609,247 is a division of application No. 18/173,124, filed on Feb. 23, 2023.
Application 18/173,124 is a division of application No. 16/793,208, filed on Feb. 18, 2020, granted, now 11,639,381.
Application 16/793,208 is a continuation of application No. PCT/US2020/012781, filed on Jan. 8, 2020.
Claims priority of provisional application 62/872,989, filed on Jul. 11, 2019.
Claims priority of provisional application 62/842,162, filed on May 2, 2019.
Claims priority of provisional application 62/789,828, filed on Jan. 8, 2019.
Prior Publication US 2024/0239880 A1, Jul. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 9/00 (2006.01); A61K 31/4172 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 47/26 (2006.01); A61P 25/06 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 9/0019 (2013.01); A61K 31/4172 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61K 47/26 (2013.01); A61P 25/06 (2018.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01)] 28 Claims
 
1. A method of treating migraine in a patient in need thereof, the method comprising intravenously administering to the patient a humanized monoclonal antibody comprising:
(A) a variable light chain polypeptide comprising light chain complementary determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO: 224, SEQ ID NO: 226, and SEQ ID NO: 228, respectively, and
(B) a variable heavy chain polypeptide comprising heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO: 204, SEQ ID NO: 206, and SEQ ID NO: 208, respectively,
wherein the humanized monoclonal antibody is administered to the patient at a dose of about 100 mg, the administration begins while the patient is experiencing a migraine attack, and the prevention of one or more symptoms is experienced by the patient within a short time period post-infusion with said antibody, such as within minutes or a few hours, such as within 10 minutes, 20 minutes, 30 minutes, 60 minutes, 1 hour, 2 hours or 6 hours.